Enanta Pharmaceuticals (ENTA) PT Lowered to $50 at RBC Capital
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street rallies after Democrats win Congress; data center stocks slide
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts ENTA Hot Sheet
Price: $10.44 +0.68%
Rating Summary:
15 Buy, 3 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 16 | Down: 25 | New: 12
Rating Summary:
15 Buy, 3 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 16 | Down: 25 | New: 12
Join SI Premium – FREE
RBC Capital analyst Brian Abrahams lowered the price target on Enanta Pharmaceuticals (NASDAQ: ENTA) to $50.00 (from $52.00) while maintaining a Sector Perform rating.
You May Also Be Interested In
- Dynatrace Inc. (DT) PT Lowered to $60 at DA Davidson
- SGHC Limited (SGHC) PT Lowered to $16 at StoneX
- Phoenix Education Partners (PXED) PT Lowered to $32 at Jefferies
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
